Global Data Sharing: Requirements from Chemical Regulation
نویسندگان
چکیده
منابع مشابه
Addressing Global Data Sharing Challenges
This issue of the Journal of Empirical Research on Human Research Ethics highlights the ethical issues that arise when researchers conducting projects in low- and middle-income countries seek to share the data they produce. Although sharing data is considered a best practice, the barriers to doing so are considerable and there is a need for guidance and examples. To that end, the authors of thi...
متن کاملData acquisition and data/knowledge sharing in global genomic studies☆
Multi-center andmulti-national collaborations are generating genomic, clinical and epidemiological datasets on ever increasing scales across global populations. Early examples include the international HapMap project and ongoing efforts include the 1000 Genomes Project, the genotyping and sequencing of whole populations or significant numbers of national of certain countries. The new initiative...
متن کاملDeriving component designs from global requirements
This paper is concerned with the early development phases of distributed applications, service compositions and workflow systems. It deals with the transformation of a global requirements model, which makes abstraction from the physical distribution of the different system functions, into a system design that identifies a certain number of distributed components. The temporal constraints of the...
متن کاملCost-Sharing Rates Increase During Deep Recession: Preliminary Data From Greece
Background Measures taken over the past four years in Greece to reduce pharmaceutical expenditure have led to significant price reductions for medicines, but have also changed patient cost-sharing rates for prescription drugs. This study attempts to capture the resulting increase in patients’ out-of-pocket (OOP) expenses for prescription drugs during the 2011-2014 period. Methods The authors ...
متن کاملA Global, Neutral Platform for Sharing Trial Data.
icine (IOM) report argues that availability of deidentified (anonymized) patient-level data from clinical trials can permit verification of original results, enhancing public trust and accountability; facilitate other critical research (e.g., evaluation of adverse event rates according to compound class or subpopulation or identification of surrogate end points); and avert duplicate trials, shi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Chemical Regulatory and Law Review
سال: 2019
ISSN: 2566-834X,2566-8412
DOI: 10.21552/icrl/2019/2/6